NASDAQ · NTLA
Healthcare · Biotechnology
$12.47
Down-$0.76 (-5.74%)
Updated Oct 31, 2026, 2:48 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NTLA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
NTLA closed at $12.47 after 21 trading sessions, up 1.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $12.88 | $13.16 | $12.04 | $12.47 | 4.09M |
| Oct 29, 2026 | $13.32 | $13.94 | $12.915 | $13.23 | 4.7M |
| Oct 28, 2026 | $12.075 | $13.34 | $11.93 | $13.32 | 4.91M |
| Oct 27, 2026 | $11.30 | $12.31 | $11.17 | $12.28 | 3.85M |
| Oct 26, 2026 | $11.24 | $11.44 | $11.0944 | $11.26 | 2.06M |
| Oct 23, 2026 | $11.00 | $11.24 | $10.58 | $11.21 | 3.57M |
| Oct 22, 2026 | $11.41 | $11.965 | $10.98 | $11.16 | 3.65M |
| Oct 21, 2026 | $11.84 | $11.91 | $11.55 | $11.65 | 2.83M |
| Oct 20, 2026 | $11.455 | $11.995 | $11.2847 | $11.84 | 3.42M |
| Oct 19, 2026 | $11.54 | $11.85 | $11.33 | $11.58 | 3.51M |
| Oct 16, 2026 | $11.60 | $11.675 | $10.91 | $11.42 | 8.24M |
| Oct 15, 2026 | $11.33 | $11.825 | $11.10 | $11.34 | 6.53M |
| Oct 14, 2026 | $11.83 | $11.87 | $11.285 | $11.43 | 5.44M |
| Oct 13, 2026 | $12.30 | $12.48 | $11.815 | $11.91 | 5.18M |
| Oct 12, 2026 | $13.08 | $13.23 | $12.565 | $12.58 | 4.38M |
| Oct 9, 2026 | $12.36 | $13.27 | $11.93 | $13.07 | 8.15M |
| Oct 8, 2026 | $11.90 | $12.64 | $11.76 | $12.60 | 13.97M |
| Oct 7, 2026 | $12.08 | $12.4099 | $11.70 | $11.71 | 8.3M |
| Oct 6, 2026 | $12.50 | $13.2189 | $12.04 | $12.37 | 7.95M |
| Oct 5, 2026 | $12.35 | $12.88 | $11.85 | $12.75 | 4.97M |
| Oct 2, 2026 | $12.42 | $12.765 | $12.095 | $12.26 | 4.5M |
The latest Smart Investors Daily articles mentioning NTLA.
Company
Market Activity
Research & News
NTLA research
Company profile and research snapshot.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Barclays | Underweight | — |
| Sep 9, 2026 | Citizens | Market Outperform | — |
| Sep 9, 2026 | Wedbush | Neutral | — |
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 25, 2026 | Citizens | Market Outperform | — |
No generated briefing is available yet.
Yahoo · Oct 21, 2026
BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics advance late-stage drug pipelines, with key regulatory decisions and clinical trial results ahead.
Yahoo · Oct 20, 2026
BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
Yahoo · Oct 18, 2026
Intellia Therapeutics has seen its stock fall sharply over several years, even as the business moves closer to potential commercialization of its gene editing therapies. This raises a clear question about whether the current share price is properly anchored to its sales base. Over the past 5 years, the share price has fallen 91.3%, which puts the focus squarely on what investors are now paying for each dollar of Intellia Therapeutics' revenue. Progress in late stage programs for hereditary...
Yahoo · Oct 13, 2026
CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical indust
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NTLA.
